NGC Update Service: October 10, 2016

ngc

October 10, 2016

New This Week

Guideline Summaries

Congress of Neurological Surgeons


Announcements

NGC Guideline Syntheses

Syntheses are systematic comparisons of selected guidelines that address similar topic areas. View NGC's Guideline Syntheses.

Topic Nomination for AHRQ's EPC Program

The Agency for Healthcare Research and Quality's Evidence-based Practice Center (EPC) Program wants to hear from you about important topics for systematic evidence reviews. You can nominate topics online until October 31.

For more information about the topic nomination process, please contact: EPC@ahrq.hhs.gov.

To see what others have suggested, visit the AHRQ Effective Healthcare Program Web site.

U.S. Food and Drug Administration (FDA) Advisories

October 4, 2016: Direct-Acting Antivirals for Hepatitis C: The FDA is warning about the risk of hepatitis B virus (HBV) becoming an active infection again in any patient who has a current or previous infection with HBV and is treated with certain direct-acting antiviral (DAA) medicines for hepatitis C virus. In a few cases, HBV reactivation in patients treated with DAA medicines resulted in serious liver problems or death. HBV reactivation usually occurred within 4-8 weeks.

How to Participate

Submit Guidelines: Visit our Submit Guidelines page for information on how to submit your organization's guidelines.

Suggest a Guideline for Possible Inclusion: Submit your suggestions for evidence-based clinical practice guidelines that you would like to see included in NGC.

NGC's Sister Resource

Look for Quality Measures in AHRQ's National Quality Measures Clearinghouse (NQMC).